Nonalcoholic fatty liver disease (NAFLD) and its progressive form ... the pathogenesis of NAFLD and the current treatment and management of nonalcoholic steatohepatitis. Currently, maintaining ...

the natural history of untreated decompensated HBV cirrhosis and risk factors associated with disease progression, (2) medical management of patients with decompensated HBV cirrhosis including the ...

Exercise is a cornerstone in managing metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study ...

Portal hypertension in cirrhosis is mainly the result of increased ... to confirm the potential of this drug for the long-term management of portal hypertension in this population”.

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously called non-alcoholic fatty liver disease, is a ...

L iver cirrhosis is a late-stage liver disease characterized by the gradual replacement of healthy liver tissue with scar tissue. This condition typically results from long-term chronic hepatitis ...

LPCN 1148 is targeted to be a "First in Class" product candidate with a novel mechanism of action for management of cirrhosis. (PRNewsfoto/Lipocine Inc.) "We are excited the FDA has recognized ...

A Cleveland Clinic liver specialist discusses life expectancy with fatty liver disease and provides tips to take charge of your health.

Treatment with LPCN 1148 in the POC study improved sarcopenia and associated clinical outcomes. LPCN 1148 is targeted to be a "First in Class" product candidate with a novel mechanism of action for ...